ArticlePediatric cardiology2026
Hemodynamic Effects of Methylene Blue in Pediatric Cardiac Critical Care Patients: A Descriptive Study of Causal Inference and Cluster Analysis Using High-Fidelity Data.
Article in Pediatric cardiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Methylene blue inhibits the nitric oxide-soluble guanylyl cyclase-cyclic GMP pathway and is used to restore vascular tone in vasoplegic circulatory failure. Its hemodynamic and oxygenation effects in children, however, remain incompletely defined. A single-center retrospective, mechanistic, physiology-focused analysis of pediatric cardiac intensive care unit patients who received methylene blue for vasoplegia was conducted. High-fidelity physiologic data were extracted from Sickbay. Percent change in vasoactive score, mean arterial blood pressure, cerebral near infrared spectroscopy, and renal near infrared spectroscopy within four hours after administration were calculated relative pre-dose baseline. Unsupervised cluster analysis identified physiologic response phenotypes, and random forest regression models were used to determine which pre-administration variables predicted response magnitude. Independent variables included vasoactive medications, fluid balance, sedation, and patient characteristics. 19 administrations across 15 unique patients were analyzed. Cluster analysis revealed 3 distinct response phenotypes including a group with significant improvement in adequacy of oxygen delivery and a group without such increase. Random forest modeling identified methylene blue dose, vasopressin dose, and epinephrine dose as important response prediction features. Calcium chloride augmented response while vasopressin blunted it. Data from this descriptive study suggest that methylene blue may improve arterial blood pressure, and adequacy of oxygen delivery in critically ill pediatric patients with vasoplegia. The greatest response occurred in patients with higher catecholamine but lower vasopressin doses, consistent with a catecholamine-responsive, nitric oxide-mediated phenotype. Calcium appeared to augment methylene blue response while vasopressin blunted it. These findings provide a physiologic framework for targeted methylene blue use in pediatric circulatory failure.
Identifiers
41874659What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.